PTPI Petros Pharmaceuticals, Inc.
Pharmaceutical Preparations · OTC · SEC CIK 1815903 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-12.2%
TTM net income YoY-75.4%
TTM EPS YoY-1,214.5%
Revenue 3-yr CAGR-13.2%
Net income 3-yr CAGR—
Margins
Gross margin76.3%
Operating margin-90.5%
Net margin-280.1%
FCF margin—
EBITDA margin-35.1%
Returns
ROE-622.1%
ROA-64.5%
ROIC (approx.)—
Asset turnover0.23x
Leverage & solvency
Liabilities / assets170.2%
Debt / equity—
Current ratio0.40x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.18x
Accruals ratio-52.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 | 2024Q32024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | $725,403 | $1.58M |
| Cost of revenue | — | — | — | — | — | — | $264,754 | $287,005 |
| Gross profit | — | — | — | — | — | — | $460,649 | $1.29M |
| R&D expense | — | — | — | — | — | — | $101,945 | $588,355 |
| SG&A expense | $988,501 | $1.03M | $391,486 | $990,737 | $1.80M | $1.46M | $577,554 | $1.20M |
| Operating income | -$988,501 | -$1.03M | -$391,486 | -$990,737 | -$1.80M | -$1.46M | -$577,554 | -$1.20M |
| Pretax income | -$955,625 | -$987,036 | -$336,506 | -$922,723 | -$2.04M | -$1.20M | -$552,813 | -$919,541 |
| Net income | -$955,625 | -$987,036 | -$336,506 | -$922,723 | $5.43M | -$2.26M | -$9.27M | -$2.22M |
| EBITDA | — | — | — | — | — | — | $78,539 | -$457,910 |
| EPS (basic) | -0.30 | -0.03 | — | -0.03 | -1.20 | -9.37 | — | -16.65 |
| EPS (diluted) | -0.30 | -0.03 | — | -0.03 | -1.20 | -9.37 | — | -16.65 |
| Weighted avg. shares (diluted) | 47.39M | 46.22M | — | 42.28M | 25.92M | 1.16M | — | 393,192 |
| Banking | ||||||||
| Net interest income | $31,976 | $40,143 | $53,280 | $67,014 | $88,849 | $47,790 | $24,741 | $75,818 |
| Balance sheet | ||||||||
| Cash & equivalents | $3.49M | $4.35M | $5.14M | $6.07M | $7.32M | $8.93M | $1.72M | $3.20M |
| Receivables | — | — | — | — | — | — | $416,076 | $1.95M |
| Inventory | — | — | — | — | — | — | $1.35M | $1.41M |
| Current assets | $3.55M | $4.39M | $5.16M | $6.13M | $7.40M | $14.47M | $7.29M | $10.72M |
| PP&E, net | — | — | — | — | — | — | $22,948 | $18,819 |
| Intangibles | — | — | — | — | — | — | $3.20M | $6.83M |
| Total assets | $3.55M | $4.39M | $5.16M | $6.13M | $7.40M | $17.61M | $10.64M | $20.69M |
| Current liabilities | $2.84M | $2.62M | $2.29M | $2.77M | $2.95M | $27.13M | $18.03M | $12.56M |
| Total liabilities | $2.84M | $2.62M | $2.29M | $2.77M | $2.95M | $27.19M | $18.10M | $17.58M |
| Shareholders' equity | $700,894 | $1.77M | $2.87M | $3.37M | $4.45M | -$9.58M | -$7.47M | $3.12M |
| Shares outstanding | 42.37M | 42.37M | 42.28M | 42.28M | 42.28M | 2.05M | 421,124 | 10.01M |
| Cash flow statement | ||||||||
| Operating cash flow | -$863,855 | -$784,272 | -$933,544 | -$1.13M | -$3.01M | -$1.66M | $965,405 | -$771,246 |
| Capital expenditure | — | — | — | — | — | — | $5,449 | — |
| Free cash flow | — | — | — | — | — | — | $959,956 | — |
| Investing cash flow | — | — | — | — | — | — | -$5,449 | — |
| Financing cash flow | — | — | $0 | -$117,311 | -$428,233 | $8.71M | -$1.14M | -$2.77M |
| Depreciation & amortization | — | — | — | — | — | — | $656,093 | $739,449 |
| Stock-based compensation | $117,906 | $120,319 | — | — | $74,321 | $80,038 | $0 | $0 |
Free plan shows the latest 8 periods; Pro shows all 26 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.